PMID- 27974674
OWN - NLM
STAT- MEDLINE
DCOM- 20180226
LR  - 20181202
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 8
IP  - 5
DP  - 2017 Jan 31
TI  - Sweyjawbu expression is a predictor of ALK rearrangement status in lymphoma.
PG  - 7914-7920
LID - 10.18632/oncotarget.13851 [doi]
AB  - In recent years molecular subtyping has become an important tool for accurate 
      diagnosis of many cancers; for example, the detection of ALK rearrangements in 
      lymphoma and lung cancer helps clinicians provide more precise diagnosis and 
      treatment. Fluorescence in situ hybridization (FISH) and immunohistochemistry 
      (IHC) are two routine approaches used to detect ALK rearrangements. However, 
      difficulties with acquisition of biopsy samples, high costs, and long waiting 
      time for results negatively impact the application of these methods. A rapid and 
      inexpensive alternative would be a useful complement to current ALK rearrangement 
      detection. We identified a novel gene, sweyjawbu, from Affymetrix microarray 
      studies. Its expression correlated strongly with ALK in an analysis of 1037 
      cancer cell lines (correlation coefficient = 0.92). By comparing sweyjawbu 
      transcript levels, it was possible to discriminate 12 ALK rearrangement-positive 
      lymphoma samples from 64 ALK rearrangement-negative lymphomas. Moreover, 
      combining measurements of sweyjawbu expression and the ratio of the 5' and 3' 
      portions of the ALK transcript provided even more accurate identification of ALK 
      rearrangement-positive lymphomas. This novel approach is an excellent complement 
      or alternative to existing FISH and IHC methodologies.
FAU - Xue, Kai
AU  - Xue K
AD  - Department of Medical Oncology, Fudan University Shanghai Cancer Center, 
      Shanghai, China.
AD  - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
      China.
FAU - Ye, Xun
AU  - Ye X
AD  - Fudan University Shanghai Cancer Center, Institut Merieux Lab, Fudan University 
      Shanghai Cancer Center, Shanghai, China.
AD  - Medical Device Development Department (MD3), bioMerieux Co., Ltd., Shanghai, 
      China.
FAU - Liu, Fang
AU  - Liu F
AD  - Fudan University Shanghai Cancer Center, Institut Merieux Lab, Fudan University 
      Shanghai Cancer Center, Shanghai, China.
FAU - Zhang, Qunlin
AU  - Zhang Q
AD  - Department of Medical Oncology, Fudan University Shanghai Cancer Center, 
      Shanghai, China.
AD  - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
      China.
FAU - Wang, Qifeng
AU  - Wang Q
AD  - Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 
      China.
AD  - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
      China.
FAU - Huang, Shan
AU  - Huang S
AD  - Department of Pathology, The First Affiliated Hospital of Soochow University, 
      Suzhou, China.
FAU - Wang, Jiachen
AU  - Wang J
AD  - Department of Medical Oncology, Fudan University Shanghai Cancer Center, 
      Shanghai, China.
AD  - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
      China.
FAU - Lu, YongMing
AU  - Lu Y
AD  - Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 
      China.
AD  - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
      China.
FAU - Guo, Ye
AU  - Guo Y
AD  - Department of Medical Oncology, Fudan University Shanghai Cancer Center, 
      Shanghai, China.
AD  - Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 
      China.
FAU - Meng, Xia
AU  - Meng X
AD  - Fudan University Shanghai Cancer Center, Institut Merieux Lab, Fudan University 
      Shanghai Cancer Center, Shanghai, China.
AD  - Medical Device Development Department (MD3), bioMerieux Co., Ltd., Shanghai, 
      China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (RNA, Messenger)
RN  - EC 2.7.10.1 (ALK protein, human)
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
SB  - IM
MH  - Anaplastic Lymphoma Kinase
MH  - Biomarkers, Tumor/*genetics/metabolism
MH  - Cell Line, Tumor
MH  - Gene Expression Profiling/methods
MH  - Gene Expression Regulation, Neoplastic
MH  - *Gene Rearrangement
MH  - Genetic Predisposition to Disease
MH  - Humans
MH  - In Situ Hybridization
MH  - Lymphoma/enzymology/*genetics/pathology
MH  - Oligonucleotide Array Sequence Analysis
MH  - Phenotype
MH  - Predictive Value of Tests
MH  - RNA, Messenger/genetics/metabolism
MH  - Real-Time Polymerase Chain Reaction
MH  - Receptor Protein-Tyrosine Kinases/*genetics
MH  - Reproducibility of Results
MH  - Transcription, Genetic
MH  - Up-Regulation
PMC - PMC5352370
OTO - NOTNLM
OT  - ALK rearrangements
OT  - lymphoma
OT  - sweyjawbu
COIS- CONFLICTS OF INTEREST The authors declare no conflicts of interest.
EDAT- 2016/12/16 06:00
MHDA- 2018/02/27 06:00
PMCR- 2017/01/31
CRDT- 2016/12/16 06:00
PHST- 2016/02/24 00:00 [received]
PHST- 2016/11/02 00:00 [accepted]
PHST- 2016/12/16 06:00 [pubmed]
PHST- 2018/02/27 06:00 [medline]
PHST- 2016/12/16 06:00 [entrez]
PHST- 2017/01/31 00:00 [pmc-release]
AID - 13851 [pii]
AID - 10.18632/oncotarget.13851 [doi]
PST - ppublish
SO  - Oncotarget. 2017 Jan 31;8(5):7914-7920. doi: 10.18632/oncotarget.13851.